Since the landmark Informing the Pathway of COPD Treatment (IMPACT) trial in 2018, 3 triple therapy inhalers comprising an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), and long-acting muscarinic antagonist (LAMA) have become widely used in COPD management.

2018年11月5日 · The randomised, double-blind, double-dummy FULFIL study compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy in 1,810 patients with COPD

Triple therapy consisted of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA), and inhaled corticosteroid (ICS).

Triple therapy (LABA + LAMA + ICS) is indicated if exacerbations persist despite one of these options. The persistence of dyspnoea despite a dual bronchodilation or of exacerbations despite a triple therapy leads to the discussion of other treatments (theophylline if dyspnoea, macrolides if exacerbations, low-dose opioids if

Triple therapy in fixed-dose combinations (FDCs), i.e., combining ICS, LABA with LAMA and administrating by a single inhalation device, has appeared in recent years. This study aims to compare the efficacy of triple therapy in FDCs in treating patients with moderate to severe COPD.

COPD patients with high blood eosinophilia, older age, more AEs in the previous year, ACO, and initial dual bronchodilator therapy were stepped up to triple therapy early. Triple therapy showed improvements in lung function of most patients switching from mono bronchodilator therapy.

• 治療穩定型COPD患者藥物包含了(1)支氣管擴張劑:其中又 細分為β2 agonist、Muscarinic antagonist、Methylxanthines (2) 吸入性類固醇(ICS)(3) PDE4抑制劑等 . • 於發生急性惡化風險較高的病人目前大部分的治療指引建 議合併不同機轉之長效支氣管擴張劑與增加單一種支氣管 擴張劑劑量相比,較能增加氣管擴張的效果且能降低副作用 . • Triple therapy(ICS+LABA+LAMA) 建議使用於已使用一種 或兩種藥物治療仍控制不佳的病人. 院內吸入劑品項. 藥理作用 外觀 商品名( …

2018年3月17日 · We aimed to compare a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) versus a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrronium (IND/GLY) in terms of the rate of moderate-to-severe COPD exacerbations over 52 weeks of treatment.

Several studies have documented that long-acting bronchodilators can reduce exacerbation rate and/or severity, and others have shown that combinations of long-acting β 2 -adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reductions in exacerbation frequency than either their monocomponents or LABA/inhaled...

2018年3月17日 · We aimed to compare a single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) versus a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrronium (IND/GLY) in terms of the rate of moderate-to-severe COPD exacerbations over 52 weeks of treatment.